--- title: "Oculis Holding (OCS) news: offering" url: "https://aibio.space/companies/oculis/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OCS offering news: Oculis reports CHF 47,775 thousand from at-the-market share sales in first half. Oculis Holding AG (NASDAQ: OCS), Switzerland." --- OCS Oculis Holding AG NASDAQ · Switzerland # Oculis Holding (OCS) news OCS offering news Financings · 2026-08-06 ## [Oculis reports CHF 47,775 thousand from at-the-market share sales in first half](https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/) Oculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026. ## Latest Oculis Holding news We have not published a story on Oculis Holding yet. When there is news, it will appear here. ## Oculis Holding at a glance - **Ticker**: OCS - **Listing**: NASDAQ - **Country**: Switzerland - **Cash, Dec 31, 2025**: CHF 82.1 million ### Related companies - [Curatis Holding](https://aibio.space/companies/curatis/) SIX: CURN - [Basilea Pharmaceutica](https://aibio.space/companies/basilea-pharmaceutica/) SIX: BSLN - [PolyPeptide Group](https://aibio.space/companies/polypeptide/) SIX: PPGN - [MindMaze Therapeutics Holding SA](https://aibio.space/companies/mindmaze-therapeutics/) SIX: MMTX - [Santhera Pharmaceuticals Holding](https://aibio.space/companies/santhera-pharmaceuticals/) SIX: SANN - [ADC Therapeutics SA](https://aibio.space/companies/adc-therapeutics/) NYSE: ADCT - [Lonza Group](https://aibio.space/companies/lonza/) SIX: LONN - [Idorsia](https://aibio.space/companies/idorsia/) SIX: IDIA ### Also on NASDAQ - [Adagio Medical Holdings](https://aibio.space/companies/adagio-medical/) ADGM - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) MBX - [Lantheus Holdings](https://aibio.space/companies/lantheus/) LNTH - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) RVMD - [biote](https://aibio.space/companies/biote/) BTMD ## Oculis Holding annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [CHF 57.1 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | [CHF 52.1 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | | Net income (loss) | [-CHF 99.0 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | [-CHF 85.8 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | | Cash from operations | [-CHF 66.3 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | [-CHF 48.9 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | | Cash and equivalents | [CHF 81.3 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | [CHF 27.7 million](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | | Short-term investments | [CHF 801,000](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | [CHF 148,000](https://www.sec.gov/Archives/edgar/data/1953530/000119312526091446/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents CHF 81.3 million, plus short-term investments of CHF 801,000, CHF 82.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Oculis Holding Has Oculis Holding raised money recently? Our latest story on this, dated Aug 6, 2026: "Oculis reports CHF 47,775 thousand from at-the-market share sales in first half". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/). What is the ticker symbol of Oculis Holding? Oculis Holding AG trades under the ticker OCS on NASDAQ. Where is Oculis Holding listed? Oculis Holding AG is listed on NASDAQ. What is the SEC CIK of Oculis Holding? The SEC Central Index Key (CIK) for Oculis Holding AG is 1953530. Its filings are on SEC EDGAR. Which country or territory is Oculis Holding listed under? Our directory records Oculis Holding AG under Switzerland. What does Oculis Holding do? Our directory classifies Oculis Holding AG as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Oculis Holding? The ISIN recorded for Oculis Holding AG is CH1242303498. Does aibio.space cover Oculis Holding? aibio.space lists Oculis Holding AG among 2,820 public biotech companies and publishes its news here as stories appear. Where is Oculis Holding incorporated? SEC records list its state or country of incorporation as V8. What is the latest Oculis Holding (OCS) stock news? Our latest story on Oculis Holding, dated Aug 6, 2026: "Oculis reports CHF 47,775 thousand from at-the-market share sales in first half". Oculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026. [Source](https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/). How long will Oculis Holding's cash last? From our story of Aug 6, 2026: The board's going-concern note says it believes current cash, cash equivalents and investments cover the company's obligations for at least the next 12 months. [Source](https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/). Is Oculis Holding a smaller reporting company? SEC records list Oculis Holding AG's filer category as: Large accelerated filer. Where is Oculis Holding headquartered? SEC records list its business address as BAHNHOFSTRASSE 7, ZUG, Switzerland, 6300. When does Oculis Holding's fiscal year end? Oculis Holding AG's fiscal year ends on December 31, per SEC records. What did Oculis Holding last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-09-30. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312526409212/board_change_6-k.htm). ## Investor discussion: Oculis Holding Members talk about Oculis Holding (OCS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Oculis Holding, newest first. Each line links the filing it comes from. 1. 2026-08-06 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312526338054/ocs-ex99_1.htm) 2. 2026-05-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/ocs-ex99_1.htm) 3. 2026-03-03 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312526088209/ocs-ex99_1.htm) 4. 2025-10-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312525260916/d66396dex991.htm) 5. 2025-08-21 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000119312525185344/ocs-ex99_1.htm) 6. 2025-03-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000095017025037201/ocs-ex99_1.htm) 7. 2025-02-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000095017025021279/ocs-ex99_1.htm) 8. 2024-11-07 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1953530/000095017024123266/ocs-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OCS on TradingView](https://www.tradingview.com/symbols/NASDAQ-OCS/). ## SEC filings and registration - **SEC name**: Oculis Holding AG - **CIK**: 1953530 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OCS (Nasdaq), OCSAW (Nasdaq) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: BAHNHOFSTRASSE 7, ZUG, Switzerland, 6300 - **Phone**: 617-937-2423 ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526409212/board_change_6-k.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526341298/project_axis_6-k.htm) filed 2026-08-10 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526338054/ocs-20260630.htm) filed 2026-08-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526282715/6-k_-_june_2026_corp_dec.htm) filed 2026-06-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526248946/6-k_-_ocs-01_diamond_res.htm) filed 2026-06-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526223970/6-k_agm_results_2026.htm) filed 2026-05-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526216741/q1_2026_6-k_fs_mda_pr.htm) filed 2026-05-11 - [6-K](https://www.sec.gov/Archives/edgar/data/1953530/000119312526166790/6-k__agm_materials_2025_.htm) filed 2026-04-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001953530), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Oculis Holding AG is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OCS, recorded under Switzerland. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Oculis Holding AG - **Ticker**: OCS - **Listing**: NASDAQ - **Country or territory**: Switzerland - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: CH1242303498 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OCS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/oculis/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oculis Holding (OCS) news: offering", 2026-10-31, https://aibio.space/companies/oculis/